Orforglipron and Gallbladder Problems: What the FDA Label Says

Yes — orforglipron (Foundayo) can raise the risk of gallbladder problems. Per its FDA-approved label on DailyMed, treatment with orforglipron and GLP-1 receptor agonists as a class is associated with an increased occurrence of acute gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). Here’s what the label actually reports, why the risk exists, and what symptoms warrant a call to your prescriber.

What the FOUNDAYO label says about gallbladder disease

Per the FDA-approved label on DailyMed, in a pool of two clinical trials for weight reduction:

• Cholelithiasis (gallstones) was reported in 1% of patients treated with orforglipron once daily, versus 0.7% of patients on placebo.
• Acute cholecystitis (gallbladder inflammation) was reported in 0.4% of patients treated with orforglipron once daily, versus 0.3% of patients on placebo.

Both figures show a small increase over placebo, not a dramatic spike — but they’re real enough that the label calls out gallbladder disease as an associated risk, and instructs that if cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.

Why GLP-1 medications are linked to gallbladder risk

Gallbladder disease with GLP-1 receptor agonists isn’t unique to orforglipron — it shows up across the class. Two things likely contribute:

1. A possible direct drug effect. GLP-1 receptor activation affects gut motility and bile-related physiology, which is one proposed mechanism behind the class-wide association with gallbladder disease.
2. Weight loss itself. Rapid or substantial weight loss — regardless of what caused it — is an independently recognized risk factor for gallstone formation. Since GLP-1 medications are prescribed specifically because they produce meaningful weight loss, some of the gallbladder risk may be tied to the weight change itself rather than the drug mechanism alone.

Because both factors point the same direction, it’s difficult to cleanly separate “the drug did this” from “the weight loss did this” — which is exactly why gallbladder risk is disclosed as an association in labeling rather than framed as a fully isolated drug effect.

Does the timing matter during titration?

Orforglipron, like other GLP-1 medications, is started at a low dose and titrated upward over months rather than prescribed at a full maintenance dose from day one. The label’s pooled trial data on cholelithiasis and cholecystitis reflects the full treatment period across that titration, not a single dose level — it doesn’t break out whether gallbladder events cluster earlier or later in treatment. If you’re mid-titration and want the general schedule for context, Foundayo (Orforglipron): A Simple Guide walks through the dosing steps; it doesn’t address gallbladder timing specifically, since the label itself doesn’t isolate it by dose or week.

Is this a GLP-1 class effect?

Yes. This isn’t specific to orforglipron. Semaglutide, sold as Ozempic and Wegovy (injection) and Rybelsus (oral tablet), and tirzepatide, sold as Mounjaro and Zepbound, are also GLP-1-pathway medications with their own gallbladder-related information in their respective drug labeling and MedlinePlus entries.

	Orforglipron (Foundayo)	Semaglutide (Ozempic/Wegovy/Rybelsus)	Tirzepatide (Mounjaro/Zepbound)
Drug class	GLP-1 receptor agonist (small molecule)	GLP-1 receptor agonist (peptide)	Dual GIP/GLP-1 receptor agonist (peptide)
Gallbladder disease noted in labeling/drug info	Yes — cholelithiasis and cholecystitis	Yes	Yes
Route	Oral tablet	Injection or oral tablet	Injection

If you’re weighing orforglipron against one of these alternatives more broadly, see Orforglipron vs Ozempic or Orforglipron vs Tirzepatide for how they compare beyond this one risk.

Symptoms that warrant a call to your prescriber

This isn’t a diagnostic checklist, and it isn’t medical advice — but the label’s guidance that cholecystitis should prompt “gallbladder studies and clinical follow-up” when suspected means new or worsening symptoms shouldn’t be self-managed or waited out. Contact your prescriber if you notice anything that concerns you, particularly persistent upper-abdominal discomfort, since gallbladder issues can sometimes be mistaken for the gastrointestinal side effects — nausea, bloating, abdominal pain — that are already common on orforglipron. If you’re trying to sort out routine GI side effects from something that needs attention, Managing Orforglipron Nausea and the full orforglipron side effects guide cover what’s typically expected during titration, which can help you and your prescriber tell “usual” apart from “worth checking.”

Who might be at higher risk

General, well-established risk factors for gallstones — independent of any GLP-1 medication — include being female, older age, obesity, and rapid weight loss. Several of these overlap with the population orforglipron is prescribed to for weight management, which is part of why this is worth knowing about rather than a reason to avoid the medication outright. Whether your personal history warrants closer monitoring is a question for your prescriber, not something to self-assess from a label percentage.

What this article won’t do

This article reports what the FDA label and MedlinePlus drug information state about gallbladder risk — it doesn’t diagnose symptoms, rank the relative risk between orforglipron and other GLP-1 drugs beyond what’s documented, or tell you whether to start, continue, or stop treatment. Those are decisions for you and your prescriber, based on your full medical history and how you’re actually feeling on the medication.

Bottom line

Orforglipron carries a small but real, FDA-documented increase in gallbladder disease risk — cholelithiasis in 1% of patients versus 0.7% on placebo, and cholecystitis in 0.4% versus 0.3% — consistent with what’s seen across GLP-1 receptor agonists as a class. It’s not a reason for alarm on its own, but it is a reason to know the symptoms worth flagging and to loop in your prescriber if something feels off rather than waiting it out. If you’re weighing this alongside orforglipron’s other known effects, our orforglipron weight loss and orforglipron and pancreatitis guides cover the other data points worth knowing before you start.